Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Change in Acquisitions & Divestments: 2017-2025

Historic Change in Acquisitions & Divestments for Altimmune (ALT) over the last 4 years, with Jun 2025 value amounting to $105.5 million.

  • Altimmune's Change in Acquisitions & Divestments rose 441.28% to $105.5 million in Q2 2025 from the same period last year, while for Jun 2025 it was $197.4 million, marking a year-over-year increase of 162.04%. This contributed to the annual value of $87.3 million for FY2024, which is 14.71% down from last year.
  • Per Altimmune's latest filing, its Change in Acquisitions & Divestments stood at $105.5 million for Q2 2025, which was up 177.47% from $38.0 million recorded in Q1 2025.
  • Altimmune's Change in Acquisitions & Divestments' 5-year high stood at $105.5 million during Q2 2025, with a 5-year trough of $14.0 million in Q1 2024.
  • Moreover, its 3-year median value for Change in Acquisitions & Divestments was $26.4 million (2023), whereas its average is $33.3 million.
  • Per our database at Business Quant, Altimmune's Change in Acquisitions & Divestments slumped by 59.50% in 2024 and then soared by 441.28% in 2025.
  • Altimmune's Change in Acquisitions & Divestments (Quarterly) stood at $25.0 million in 2021, then reached $25.9 million in 2023, then increased by 3.78% to $26.8 million in 2024, then surged by 441.28% to $105.5 million in 2025.
  • Its last three reported values are $105.5 million in Q2 2025, $38.0 million for Q1 2025, and $26.8 million during Q4 2024.